- Previous Close
2.7800 - Open
2.6400 - Bid 2.7400 x --
- Ask 3.2000 x --
- Day's Range
2.6400 - 2.6400 - 52 Week Range
2.2600 - 5.4000 - Volume
2,000 - Avg. Volume
0 - Market Cap (intraday)
50.74M - Beta (5Y Monthly) 0.77
- PE Ratio (TTM)
-- - EPS (TTM)
-0.6400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter. The company is developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma. In addition, it develops biologic platform to deliver immunomodulatory molecules directly to the tumor by infiltrating monocytes/macrophages. Genenta Science S.p.A. was incorporated in 2014 and is headquartered in Milan, Italy.
www.genenta.comRecent News: K5F.F
Performance Overview: K5F.F
Trailing total returns as of 6/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: K5F.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: K5F.F
Valuation Measures
Market Cap
53.43M
Enterprise Value
34.65M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.48
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.29%
Return on Equity (ttm)
-45.16%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-11.65M
Diluted EPS (ttm)
-0.6400
Balance Sheet and Cash Flow
Total Cash (mrq)
18.78M
Total Debt/Equity (mrq)
0.13%
Levered Free Cash Flow (ttm)
-7.58M